ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
SPRY on Nasdaq
Shares outstanding
98,567,360
Price per share
$11.65
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
83,632,743
Holdings value
$840,434,931
% of all portfolios
0%
Share change
-894,901
Value change
-$93,310,823
Average buys %
+0%
Average sells %
-0%
Number of holders
187
Price from insider filings
$8.71
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 11% $111,050,917 10,940,977 RA Capital Management, L.P. 29 Sep 2025
Flynn James E 7.8% -12% $101,139,784 -$13,599,923 7,610,217 -12% Deerfield Management Company, L.P. 30 Jul 2025
As of 30 Sep 2025, ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 187 institutional shareholders filing 13F forms. They hold 83,632,743 shares of 98,567,360 outstanding shares (85%) .

Top 25 institutional shareholders own 72% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 11% 10,860,977 0% 1.3% $109,152,819
ORBIMED ADVISORS LLC 8.4% 8,288,510 0% 2% $83,299,526
DEERFIELD MANAGEMENT COMPANY, L.P. 7.6% 7,503,812 -23% 1.2% $75,413,311
BlackRock, Inc. 4.9% 4,831,327 +9.2% 0% $48,554,836
Rubric Capital Management LP 4.6% 4,500,000 +248% 0.61% $45,225,000
SR One Capital Management, LP 4.1% 4,012,903 0% 5.8% $40,329,675
VANGUARD GROUP INC 3.6% 3,500,303 +7.3% 0% $35,178,046
Aberdeen Group plc 3.1% 3,097,022 +106% 0.05% $31,125,071
STATE STREET CORP 2.9% 2,895,256 +32% 0% $29,097,323
ALLIANCEBERNSTEIN L.P. 2.7% 2,642,111 -31% 0.01% $26,553,216
FRANKLIN RESOURCES INC 2.4% 2,398,012 +31% 0.01% $24,100,021
Casdin Capital, LLC 1.6% 1,600,000 1.3% $16,080,000
CITADEL ADVISORS LLC 1.6% 1,586,033 -29% 0.01% $15,939,632
GEODE CAPITAL MANAGEMENT, LLC 1.5% 1,505,617 +12% 0% $15,134,147
Southpoint Capital Advisors LP 1.5% 1,500,000 -12% 0.4% $15,075,000
GOLDMAN SACHS GROUP INC 1.3% 1,325,739 -9.5% 0% $13,323,677
MPM BIOIMPACT LLC 1.3% 1,303,399 0% 2.1% $13,099,160
BAMCO INC /NY/ 1.3% 1,268,532 +3071% 0.03% $12,748,747
Janney Montgomery Scott LLC 1.2% 1,213,020 +105% 0.03% $12,191,000
Qube Research & Technologies Ltd 1% 1,034,798 0.01% $10,399,720
Eversept Partners, LP 0.99% 976,511 0.75% $9,813,936
LEVIN CAPITAL STRATEGIES, L.P. 0.78% 764,294 +164% 0.7% $7,681,155
RAYMOND JAMES FINANCIAL INC 0.77% 756,347 +12% 0% $7,601,289
FMR LLC 0.75% 742,508 -53% 0% $7,462,205
MORGAN STANLEY 0.71% 700,414 +83% 0% $7,039,160

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 131,191 $1,528,610 +$771,703 $11.65 4
2025 Q3 83,632,743 $840,434,931 -$93,310,823 $10.05 187
2025 Q2 84,521,210 $1,475,027,148 +$149,943,861 $17.45 185
2025 Q1 76,226,291 $958,937,526 +$63,838,690 $12.58 182
2024 Q4 71,292,479 $752,189,524 +$68,713,805 $10.55 162
2024 Q3 63,765,651 $925,913,628 +$31,044,529 $14.50 150
2024 Q2 62,550,973 $532,326,267 +$21,937,880 $8.51 112
2024 Q1 59,892,346 $612,088,367 -$15,900,636 $10.22 114
2023 Q4 65,382,794 $358,295,677 -$2,996,255 $5.48 98
2023 Q3 66,513,560 $251,422,250 +$40,292,023 $3.78 95
2023 Q2 54,828,312 $367,348,434 +$9,833,535 $6.70 92
2023 Q1 53,405,274 $347,669,060 +$19,448,534 $6.51 88
2022 Q4 50,164,476 $427,856,540 +$173,112,713 $8.53 72
2022 Q3 30,422,729 $160,376,408 +$24,985,672 $5.28 57
2022 Q2 26,061,019 $110,514,000 -$871,564 $4.24 60
2022 Q1 26,983,278 $94,705,000 -$19,319,881 $3.51 65
2021 Q4 30,103,833 $200,460,000 -$13,222,400 $6.66 72
2021 Q3 28,894,700 $288,363,500 -$42,491,222 $9.98 74
2021 Q2 27,989,545 $864,603,729 -$826,724 $30.89 74
2021 Q1 27,691,681 $1,205,835,321 +$139,057,529 $43.63 66
2020 Q4 24,422,607 $1,126,537,026 +$1,116,076,476 $46.34 60